Compare Stocks: NRXP, OCS, ASMB, and TLRY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$23.53 +3.1%	$28.82	$21.80 ▼ $39.71	$464.64M	1.15	375,167 shs	170,489 shs
NRXP NRx Pharmaceuticals	$2.85 -1.4%	$3.28	$1.62 ▼ $5.05	$125.12M	2.07	699,710 shs	289,297 shs
OCS Oculis	$8.34 -3.7%	$11.23	$8.30 ▼ $34.47	$502.14M	0.62	295,693 shs	161,880 shs
TLRY Tilray Brands	$3.54 -1.4%	$4.29	$3.38 ▼ $20.20	$488.97M	1.91	4.18 million shs	5.72 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	+3.11%	+4.39%	-28.41%	-14.12%	-7.73%
NRXP NRx Pharmaceuticals	-1.38%	-1.72%	-15.43%	-31.98%	-20.39%
OCS Oculis	-3.70%	-4.47%	-27.29%	-38.81%	-58.03%
TLRY Tilray Brands	-1.39%	-1.94%	-15.91%	-19.91%	-79.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$23.53 +3.1%	$28.82	$21.80 ▼ $39.71	$464.64M	1.15	375,167 shs	170,489 shs
NRXP NRx Pharmaceuticals	$2.85 -1.4%	$3.28	$1.62 ▼ $5.05	$125.12M	2.07	699,710 shs	289,297 shs
OCS Oculis	$8.34 -3.7%	$11.23	$8.30 ▼ $34.47	$502.14M	0.62	295,693 shs	161,880 shs
TLRY Tilray Brands	$3.54 -1.4%	$4.29	$3.38 ▼ $20.20	$488.97M	1.91	4.18 million shs	5.72 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	+3.11%	+4.39%	-28.41%	-14.12%	-7.73%
NRXP NRx Pharmaceuticals	-1.38%	-1.72%	-15.43%	-31.98%	-20.39%
OCS Oculis	-3.70%	-4.47%	-27.29%	-38.81%	-58.03%
TLRY Tilray Brands	-1.39%	-1.94%	-15.91%	-19.91%	-79.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.83	Moderate Buy	$47.50	101.87% Upside
NRXP NRx Pharmaceuticals	2.43	Hold	$34.50	1,110.53% Upside
OCS Oculis	2.80	Moderate Buy	$39.44	372.95% Upside
TLRY Tilray Brands	2.38	Hold	$5.90	66.67% Upside

Current Analyst Ratings Breakdown

Latest NRXP, OCS, ASMB, and TLRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	TLRY Tilray Brands	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$4.50 ➝ $4.00
10/8/2026	TLRY Tilray Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
10/5/2026	TLRY Tilray Brands	TD Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.70 ➝ $4.50
9/29/2026	TLRY Tilray Brands	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/21/2026	TLRY Tilray Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/21/2026	TLRY Tilray Brands	ATB Cormark Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$8.00 ➝ $6.00
9/18/2026	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$26.00 ➝ $39.00
9/14/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
9/1/2026	ASMB Assembly Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$53.00
9/1/2026	ASMB Assembly Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$52.00
9/1/2026	ASMB Assembly Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$52.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$74.85M	6.40	N/A	N/A	$13.04 per share	1.80
NRXP NRx Pharmaceuticals	$1.23M	100.33	N/A	N/A	($0.54) per share	-5.28
OCS Oculis	N/A	N/A	N/A	N/A	$4.08 per share	N/A
TLRY Tilray Brands	$915.45M	0.53	N/A	N/A	$13.68 per share	0.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$6.12M	$1.02	23.07	470.60	N/A	-0.06%	-0.02%	-0.02%	11/9/2026 (Estimated)
NRXP NRx Pharmaceuticals	-$28.62M	-$0.55	N/A	N/A	N/A	-691.81%	N/A	-63.92%	11/13/2026 (Estimated)
OCS Oculis	-$119.44M	-$1.74	N/A	N/A	N/A	-6,777.18%	-42.61%	-35.23%	11/5/2026 (Estimated)
TLRY Tilray Brands	-$121.40M	-$1.08	N/A	N/A	N/A	-16.91%	-10.47%	-7.52%	N/A

Latest NRXP, OCS, ASMB, and TLRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	OCS Oculis	-$0.49	N/A	N/A	N/A	$0.25 million	N/A
8/14/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.1067	-$0.44	-$0.3333	-$0.44	$1.33 million	$1.10 million
8/13/2026	Q2 2026	ASMB Assembly Biosciences	-$0.7242	-$0.20	+$0.5242	-$0.20	$8.60 million	$13.37 million
8/6/2026	Q2 2026	OCS Oculis	-$0.48	-$0.20	+$0.28	-$0.20	$0.22 million	$0.38 million
7/28/2026	Q4 2026	TLRY Tilray Brands	-$0.0120	-$0.43	-$0.4180	-$0.43	$246.30 million	$281.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	13.99	13.99
NRXP NRx Pharmaceuticals	N/A	0.86	0.86
OCS Oculis	0.01	8.35	8.35
TLRY Tilray Brands	0.22	2.21	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
NRXP NRx Pharmaceuticals	4.27%
OCS Oculis	22.30%
TLRY Tilray Brands	9.35%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	3.50%
NRXP NRx Pharmaceuticals	6.40%
OCS Oculis	N/A
TLRY Tilray Brands	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	73	20.36 million	19.65 million	Optionable
NRXP NRx Pharmaceuticals	29	43.30 million	40.53 million	Optionable
OCS Oculis	60	57.98 million	N/A	Not Optionable
TLRY Tilray Brands	3,595	136.20 million	134.03 million	Optionable

NRXP, OCS, ASMB, and TLRY Headlines

Recent News About These Companies

Tilray Brands (NASDAQ:TLRY) Stock Falls 1.4% After Analyst Downgrade

October 9 at 4:59 PM | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Stock Price Target Lowered at Canaccord Genuity Group

October 9 at 2:05 PM | marketbeat.com

Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform

...

October 9 at 11:25 AM | marketbeat.com

Should you sell your Tilray stock?

October 9 at 10:16 AM | cantechletter.comC

Company News for Oct 9, 2026

October 9 at 10:16 AM | finance.yahoo.com

Following Tilray Earnings, Here's What Comes Next for TLRY Stock

October 8 at 11:07 PM | barchart.com

Tilray (TLRY) Q1 2027 Earnings Call Transcript

October 8 at 11:07 PM | fool.com

Tilray Brands Swings to Adjusted Loss in Fiscal 2027 Q1

October 8 at 6:06 PM | finance.yahoo.com

Tilray Brands Q1 revenue rises 23% to $257.1 million as beverage sales surge following BrewDog acquisition

October 8 at 6:06 PM | msn.com

Tilray Brands (TLRY) Stock: Drops as Q1 Net Loss Hits $40M and Revenue Jumps 23%

October 8 at 6:06 PM | blockonomi.com

Tilray Brands (NASDAQ:TLRY) Stock Falls 3.2% - Should You Sell?

October 8 at 5:39 PM | marketbeat.com

Tilray Brands, Inc. (TLRY) Q1 2027 Earnings Call Transcript

October 8 at 3:00 PM | seekingalpha.com

Tilray Brands Q1 Earnings Call Highlights

October 8 at 12:01 PM | marketbeat.com

Promising Cannabis Stocks To Research - October 8th

October 8 at 12:01 PM | marketbeat.com

Tilray revenue rises as beverage business drives record quarterly sales

October 8 at 11:11 AM | proactiveinvestors.com

Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease

October 8 at 10:09 AM | 247wallst.com

Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Misses Revenue Estimates

October 8 at 9:11 AM | zacks.com

Tilray posts Q1 revenue miss as cannabis sales drop

October 8 at 8:05 AM | seekingalpha.com

Tilray Brands Delivers Record Q1 Fiscal 2027 Revenue and Record Q1 Gross Profit, Demonstrating the Power of Its Global Platform, Driven by Double-Digit Year-Over-Year Growth Across International Cannabis, Beverage and Pharmaceutical Distribution

October 8 at 8:05 AM | finance.yahoo.com

October 8 at 7:00 AM | globenewswire.com

Dear Tilray Stock Fans, Mark Your Calendars for October 8

October 7 at 6:16 PM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NRXP, OCS, ASMB, and TLRY Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$23.53 +0.71 (+3.11%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$23.49 -0.04 (-0.17%)

As of 10/9/2026 07:30 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

NRx Pharmaceuticals NASDAQ:NRXP

$2.85 -0.04 (-1.38%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.85 +0.00 (+0.07%)

As of 10/9/2026 08:00 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Oculis NASDAQ:OCS

$8.34 -0.32 (-3.70%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$8.36 +0.02 (+0.24%)

As of 10/9/2026 06:23 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Tilray Brands NASDAQ:TLRY

$3.54 -0.05 (-1.39%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.53 -0.01 (-0.25%)

As of 10/9/2026 07:58 PM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRXP, OCS, ASMB, and TLRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRXP, OCS, ASMB, and TLRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRXP, OCS, ASMB, and TLRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NRXP, OCS, ASMB, and TLRY Company Descriptions

Assembly Biosciences NASDAQ:ASMB

NRx Pharmaceuticals NASDAQ:NRXP

Oculis NASDAQ:OCS

Tilray Brands NASDAQ:TLRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRXP, OCS, ASMB, and TLRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRXP, OCS, ASMB, and TLRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRXP, OCS, ASMB, and TLRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NRXP, OCS, ASMB, and TLRY Company Descriptions

Assembly Biosciences NASDAQ:ASMB

NRx Pharmaceuticals NASDAQ:NRXP

Oculis NASDAQ:OCS

Tilray Brands NASDAQ:TLRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools